Sarclisa under FDA priority review as first-line myeloma therapy

The U.S. Food and Drug Administration (FDA) has granted priority review to Sanofi’s application of Sarclisa (isatuximab) in combination with standard of care for…

Abecma OK’d in US to take earlier in treatments for multiple myeloma

The U.S. Food and Drug Administration (FDA) has expanded the indication of Abecma (idecabtagene vicleucel) to allow its use earlier in the therapy regimen…

CAR T-cell therapy recommended as earlier treatment line for RRMM

An advisory committee of the U.S. Food and Drug Administration (FDA) has unanimously recommended extending the approval of Janssen’s Carvykti (ciltacabtagene autoleucel) as an…

Phase 1b trial of STAR-LLD combo for myeloma approved by FDA

The U.S. Food and Drug Administration (FDA) has cleared the launch of a Phase 1b trial to test STAR-LLD, Starton Therapeutics’ experimental continuous delivery…